This paper presents a reflection based on 15 years' experience of studies on the pharmacology of medicinal plants in an underdeveloped country, Brazil. In these countries the investment in research is small and frequently interrupted. There is no new-medicines development program. Brazilian pharmaceutical companies have been short-sighted and have not developed new drugs. Although the diversity of the Brazilian flora is a remarkable opportunity for the development of new medicine products, natural product research is limited to a small group. These difficulties are common to all underdeveloped countries. Strategies for the pharmacological study of medicinal plants are proposed, the main difficulties are identified and a discussion of possible ways to overcome them is presented.5441700131138